What's the future of med tech? Here's a look at some of the most outlandish and perhaps forward-thinking devices in the works.
In 2012, an immediate action plan as well as new medical device legislation were proposed in the European Union. This week, the Employment, Social Policy, Health and Consumer Affairs Council of the European Commission declared the action plan a success and issued its vision for upcoming legislative changes.
Medtronic is looking forward to reaping the benefits of its new Irish domicile after its $42.9 purchase of Covidien, but the tax inversion process will not be all fun and games, according to tax experts.
Amid the current M&A feeding frenzy going on in the medical device jungle Danaher is the 800-pound gorilla quietly sitting on its hands as well as an estimated $12 billion available to make a deal--or several.
2013 marked a bleak year for med tech IPOs, with only four device companies making their market debut. But the backward trend could be on the upswing, as companies are cashing in their chips with plans to go public.
U.S. diabetes patients are much more likely to use a vial and syringe than Europeans, who prefer a prefilled pen. Diabetes powerhouse Novo Nordisk is looking to remedy that situation with the introduction of a new, easier-to-use pen onto the U.S. market: the Levemir FlexTouch.
An estimated 10,000 genomes and exomes will be sequenced this year in a clinical setting. But all that data only leads to a diagnosis about a quarter of the time. This testing is most useful for patients with rare disorders that result from variants in a single gene, according to a new paper published in the New England Journal of Medicine from two NIH scientists.
Johnson & Johnson committed to financing early stage companies through its Innovation Centers scattered around the globe that launched more than a year ago. Now it's unveiling a dozen alliances that it has made lately with life science companies and research institutions.
Head of the Scripps Translational Science Institute Eric Topol--a distinguished cardiologist and genomic researcher--says that med tech can make medicine more transparent, as well as help patients make more informed decisions.
Medtronic successfully implanted its tiny leadless cardiac pacemaker in its first patients as part of a global clinical trial, chalking up another victory for the device on its path toward regulatory approval.
Covidien has issued a recall of its Hydrofinity Hydrophilic Guidewire due to the potential for damage to the outer polymer jackets of the device during use. The company said it has notified the FDA of the action.
Now that Medtronic has grabbed Covidien for $42.9 billion, Covidien's endovascular unit could be on the line as the companies chart a course of action for their pending merger.
Medtronic has presented a study demonstrating that its implantable defibrillator, which includes a proprietary algorithm that personalizes treatment to an individual, is safer and requires less follow-up healthcare than the conventional version.
Investors made an infusion of $64 million into Benvenue Medical on the heels of an FDA approval and U.S. launch of a new device earlier this year. In January, FDA approved its Kiva VCF Treatment System, an implant to treat vertebral compression fractures and the company launched the product in March.
If approved, EnteroMedics' vagal nerve blocker would be the first new device to treat obesity in the U.S. in over a decade. But the FDA Gastroenterology and Urology Device panel narrowly voted against its Maestro System on the crucial issue of efficacy in a 4-to-5 vote on June 17.
The Internet of Things--the physical devices that are connected to the internet--is catching on not only in the tech world but also in the healthcare industry.
Covidien shareholders might be popping the bubbly in light of the company's $42.9 billion sale to Medtronic, but top-level management also has a reason to celebrate. Financial filings show that the deal could result in a hefty payout for Covidien's senior executive team if they leave the company once the merger is complete.
The FDA has told Boston Scientific its Watchman implant designed to help prevent strokes in atrial fibrillation patients will have to face a third advisory panel before gaining approval.
As mobile medical apps and devices gain market traction, lawmakers are stepping up with questions about how to best regulate the devices.
Belgian 3-D printer Materialise is planning a $104 million IPO on NASDAQ during the week of June 23. Medical devices account for much of its revenue, but it also does industrial work.